A number of investment brokers have recently updated their price targets on shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/08/2016 – BioMarin Pharmaceutical Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 116 price target on the stock.

04/06/2016 – BMO Capital Markets began new coverage on BioMarin Pharmaceutical Inc. giving the company a “outperform” rating. They now have a USD 99 price target on the stock.

04/05/2016 – BioMarin Pharmaceutical Inc. had its “perform” rating reiterated by analysts at Oppenheimer. They now have a USD 99 price target on the stock.

03/28/2016 – BioMarin Pharmaceutical Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 107 price target on the stock.

03/22/2016 – BioMarin Pharmaceutical Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 109 price target on the stock.

03/22/2016 – BioMarin Pharmaceutical Inc. had its “neutral” rating reiterated by analysts at Wedbush. They now have a USD 108 price target on the stock.

03/21/2016 – BioMarin Pharmaceutical Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 120 price target on the stock.

03/07/2016 – BioMarin Pharmaceutical Inc. was upgraded to “outperform” by analysts at Robert W. Baird. They now have a USD 110 price target on the stock.

03/07/2016 – BioMarin Pharmaceutical Inc. was upgraded to “conviction buy” by analysts at Goldman Sachs. They now have a USD 129 price target on the stock.

03/03/2016 – BioMarin Pharmaceutical Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 107 price target on the stock.

02/26/2016 – BioMarin Pharmaceutical Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 117 price target on the stock.

02/26/2016 – BioMarin Pharmaceutical Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 125 price target on the stock.

02/26/2016 – BioMarin Pharmaceutical Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 105 price target on the stock.

01/15/2016 – BioMarin Pharmaceutical Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 135 price target on the stock.

12/10/2015 – BioMarin Pharmaceutical Inc. had its “buy” rating reiterated by analysts at Cowen. They now have a USD 175 price target on the stock.

The share price of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was up +0.07% during the last day of trading, with a day high of 82.35. 795315 shares were traded during the last session.

The stock’s 50 day moving average is 84.85 and its 200 day moving average is 90.66. The stock’s market capitalization is 13.05B. BioMarin Pharmaceutical Inc. has a 52-week low of 62.12 and a 52-week high of 151.75.

View other investors thoughts on BioMarin Pharmaceutical Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.